2 results
Approved WMOCompleted
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Approved WMOCompleted
to assess the efficacy, safety, and immunogenicity of bivalent RSVpreF or placebo (1:1 randomization) in infants born to healthy women vaccinated during pregnancy, as well as the safety and immunogenicity in the pregnant women.